Arca
Skip to content
Tools
Tools

C3: Complement C3

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Precursor of non-enzymatic components of the classical, alternative, lectin and GZMK complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. {ECO:0000269|PubMed:12878586, ECO:0000269|PubMed:18204047, ECO:0000269|PubMed:28264884, ECO:0000269|PubMed:31507604, ECO:0000269|PubMed:39814882, ECO:0000269|PubMed:39914456, ECO:0000269|PubMed:624565, ECO:0000269|PubMed:6554279}.

  • Drugs that act on it: 3
  • Approved: 1
  • In phases 1 to 3: 2
  • Sponsors: 3

Who Is On It, and How Far Along

Every drug ChEMBL records acting on C3, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide
  • Other

Approved1

  • Pegcetacoplan

Phase 30

    Phase 22

    • AL-78898A
    • AMY-101

    Phase 10

      The Landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Complement C3 inhibitor.
      PegcetacoplanApprovedApellis PharmaceuticalsProtein or peptideInhibitor—14Boxed warning
      AL-78898APhase 2AlconOtherInhibitor—0—
      AMY-101Phase 2Amyndas Pharmaceuticals S.A.Protein or peptideInhibitor—0—

      Open Trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      Pilot STUDY to Monitor Ex-vivo the Biological Effects of the C3 Inhibitor, PEGCETACOPLAN, on Activation of Complement in Fluid Phase and on Podocytes in Patients With C3G and Primary IC-MPGNPegcetacoplan—Not yet recruitingMario Negri Institute for Pharmacological Research2026-10-29
      A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant RecipientsPegcetacoplanPhase 3RecruitingSwedish Orphan Biovitrum2026-10-27
      Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country StudyPegcetacoplanPhase 4RecruitingSwedish Orphan Biovitrum2026-08-05
      Lesion-tailored, Fundus-controlled Perimetry in Geographic Atrophy (GA).Pegcetacoplan—RecruitingUniversity of Utah2026-05-12
      Safely Quenching Complement in Stroke SurvivorsPegcetacoplanPhase 1Not yet recruitingColumbia University2026-03-27
      A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular DegeneratioPegcetacoplanPhase 2RecruitingApellis Pharmaceuticals, Inc.2025-10-10
      Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal AdenocarcinomaPegcetacoplanPhase 1 / Phase 2RecruitingRoswell Park Cancer Institute2025-10-09
      Home Reported Outcomes in PNHPegcetacoplan—RecruitingNovartis Pharmaceuticals2024-05-13

      Diseases Most Associated With It

      Open Targets association score, 0 to 1; all associations
      Atypical hemolytic-uremic syndrome with C3 anomaly
      0.80
      Complement component 3 deficiency
      0.77
      Age-related macular degeneration
      0.74
      Complement 3 glomerulopathy
      0.60
      Atypical hemolytic-uremic syndrome
      0.59
      Age related macular degeneration 9
      0.56
      Retinal disorder
      0.56
      Atrophic macular degeneration
      0.55
      Degeneration of macula and posterior pole
      0.54

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4917, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P01024, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.